Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives.

Costa R, Carneiro BA, Wainwright DA, Santa-Maria CA, Kumthekar P, Chae YK, Gradishar WJ, Cristofanilli M, Giles FJ.

Ann Oncol. 2017 Jan 1;28(1):44-56. doi: 10.1093/annonc/mdw532. Review.

PMID:
28177431
2.

Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib.

Tomasello G, Bedard PL, de Azambuja E, Lossignol D, Devriendt D, Piccart-Gebhart MJ.

Crit Rev Oncol Hematol. 2010 Aug;75(2):110-21. doi: 10.1016/j.critrevonc.2009.11.003. Epub 2009 Dec 9. Review.

PMID:
20004109
3.

New target therapies for brain metastases from breast cancer.

Metro G, Fabi A.

Curr Cancer Drug Targets. 2012 Mar;12(3):210-7. Review.

PMID:
22268385
4.

[Brain metastasis of breast tumors and blood brain barrier].

Diéras V, Pierga JY.

Bull Cancer. 2011 Apr;98(4):385-9. doi: 10.1684/bdc.2011.1336. Review. French.

5.

Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer.

Chien AJ, Rugo HS.

Breast Cancer Res Treat. 2013 Jan;137(1):1-12. doi: 10.1007/s10549-012-2328-6. Epub 2012 Nov 10. Review.

6.

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.

Bachelot T, Romieu G, Campone M, Diéras V, Cropet C, Dalenc F, Jimenez M, Le Rhun E, Pierga JY, Gonçalves A, Leheurteur M, Domont J, Gutierrez M, Curé H, Ferrero JM, Labbe-Devilliers C.

Lancet Oncol. 2013 Jan;14(1):64-71. doi: 10.1016/S1470-2045(12)70432-1. Epub 2012 Nov 2.

PMID:
23122784
7.

Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier.

Mehta AI, Brufsky AM, Sampson JH.

Cancer Treat Rev. 2013 May;39(3):261-9. doi: 10.1016/j.ctrv.2012.05.006. Epub 2012 Jun 22. Review.

8.

Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.

Pierga JY, Bidard FC, Cropet C, Tresca P, Dalenc F, Romieu G, Campone M, Mahier Aït-Oukhatar C, Le Rhun E, Gonçalves A, Leheurteur M, Dômont J, Gutierrez M, Curé H, Ferrero JM, Labbe-Devilliers C, Bachelot T.

Ann Oncol. 2013 Dec;24(12):2999-3004. doi: 10.1093/annonc/mdt348. Epub 2013 Sep 6.

PMID:
24013510
9.

Central nervous system involvement in breast cancer patients: Is the therapeutic landscape changing too slowly?

Fontanella C, De Carlo E, Cinausero M, Pelizzari G, Venuti I, Puglisi F.

Cancer Treat Rev. 2016 May;46:80-8. doi: 10.1016/j.ctrv.2016.03.014. Epub 2016 Apr 1. Review.

PMID:
27218867
10.

Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases.

Liu MC, Cortés J, O'Shaughnessy J.

Cancer Metastasis Rev. 2016 Jun;35(2):323-32. doi: 10.1007/s10555-016-9619-z. Review.

PMID:
27023712
11.

Current therapeutic options for breast cancer central nervous system metastases.

Hemphill MB, Lawrence JA.

Curr Treat Options Oncol. 2008 Feb;9(1):41-50. doi: 10.1007/s11864-008-0056-2. Epub 2008 Apr 5. Review.

PMID:
18392684
12.

Brain-metastatic Breast Cancer: Clinical Considerations and Pharmacological Approaches.

Andrade AC, Ferruzzi DS, Panis C.

Anticancer Agents Med Chem. 2016;16(12):1523-1528. Review.

PMID:
27039922
13.

Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.

Wiens AL, Martin SE, Bertsch EC, Vance GH, Stohler RA, Cheng L, Badve S, Hattab EM.

Arch Pathol Lab Med. 2014 Feb;138(2):175-81. doi: 10.5858/arpa.2012-0541-OA.

PMID:
24476516
14.

Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?

Teplinsky E, Esteva FJ.

Curr Oncol Rep. 2015 Oct;17(10):46. doi: 10.1007/s11912-015-0471-z. Review.

PMID:
26314739
15.

New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer.

Melisko ME, Glantz M, Rugo HS.

Nat Clin Pract Oncol. 2009 Jan;6(1):25-33. doi: 10.1038/ncponc1243. Epub 2008 Oct 21. Review.

PMID:
18936791
16.

Optimal management of brain metastases from breast cancer. Issues and considerations.

Bartsch R, Berghoff AS, Preusser M.

CNS Drugs. 2013 Feb;27(2):121-34. doi: 10.1007/s40263-012-0024-z. Review.

PMID:
23239265
17.

A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience.

McKee MJ, Keith K, Deal AM, Garrett AL, Wheless AA, Green RL, Benbow JM, Dees EC, Carey LA, Ewend MG, Anders CK, Zagar TM.

Oncologist. 2016 Jan;21(1):16-20. doi: 10.1634/theoncologist.2015-0328. Epub 2015 Dec 9.

18.

Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases.

Niwińska A, Murawska M, Pogoda K.

Cancer. 2010 Sep 15;116(18):4238-47. doi: 10.1002/cncr.25391.

19.

Clinical predictors of long-term survival in HER2-positive metastatic breast cancer.

Murthy P, Kidwell KM, Schott AF, Merajver SD, Griggs JJ, Smerage JD, Van Poznak CH, Wicha MS, Hayes DF, Henry NL.

Breast Cancer Res Treat. 2016 Feb;155(3):589-95. doi: 10.1007/s10549-016-3705-3. Epub 2016 Feb 13.

20.

Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis.

Hayashi N, Niikura N, Masuda N, Takashima S, Nakamura R, Watanabe K, Kanbayashi C, Ishida M, Hozumi Y, Tsuneizumi M, Kondo N, Naito Y, Honda Y, Matsui A, Fujisawa T, Oshitanai R, Yasojima H, Yamauchi H, Saji S, Iwata H.

Breast Cancer Res Treat. 2015 Jan;149(1):277-84. doi: 10.1007/s10549-014-3237-7. Epub 2014 Dec 21.

PMID:
25528021

Supplemental Content

Support Center